- Dr. Kronenberg brings 25 years of legal experience, with 20 years in the pharmaceutical industry
- Oliver Strub appointed as Head of Compliance
Pratteln, Switzerland, July 31, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the Board of Directors has appointed Dr. Oliver P. Kronenberg as Chief Legal Officer and Corporate Secretary of Santhera Pharmaceuticals AG, effective August 1, 2024.
As a member of the executive management team, Dr. Oliver P. Kronenberg will lead the Company's legal strategy and global legal activities, including transactions, corporate governance, and IP. He succeeds Oliver Strub, who remains at Santhera and will assume the newly created role of Head of Compliance, where he will be responsible for overseeing the development, implementation and management of Santhera’s compliance program.
“We are pleased to welcome Oliver to Santhera as Chief Legal Officer and as a member of our executive leadership team,” commented Dr. Thomas Meier, Chairman of the Board of Santhera. “His expertise and achievements in key legal areas of the life sciences industry strengthens our leadership team, increasing our expertise in corporate governance and knowledge in the approval and market launch of pharmaceutical products. We extend our deepest thanks to Oliver Strub, who has led Santhera’s legal department since 2006 and will continue as Head of Compliance, where his focus will be on overseeing Santhera’s compliance program.”
Dr. Oliver P. Kronenberg is a lawyer with more than 25 years of experience, including over 20 years in the international pharmaceutical industry. Since 2008 he has worked in various roles at Vifor Pharma and its parent company, Galenica. As Head of Legal and Compliance at Vifor Pharma, he was responsible for establishing the legal, IP, and compliance department. In 2013, he was promoted to Group General Counsel of Galenica. After the split of the Galenica Group in April 2017, he returned to Vifor Pharma, becoming Group General Counsel and was appointed member of the executive committee in 2022. Dr. Kronenberg has supported Santhera since April 2024 as interim General Counsel.
Dr. Oliver P. Kronenberg commented: “I am excited to be joining Santhera at this important stage of its development, as momentum builds towards the continuous launch of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy. I look forward to working closely with the executive team and the Board in the months ahead.”
Dr. Kronenberg holds a doctorate in law from the University of Basel, an LL.M. degree from the College of Europe in Bruges, Belgium, a degree in Finance for Executives from INSEAD, and an IMD Board Director Diploma.
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), and in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). Santhera has out-licensed rights to vamorolone for North America to Catalyst Pharmaceuticals and for China to Sperogenix Therapeutics. For further information, please visit www.santhera.com.
AGAMREE® is a trademark of Santhera Pharmaceuticals.
For further information please contact:
public-relations@santhera.com or
Eva Kalias, Head Investor Relations & Communications
Phone: +41 79 875 27 80
eva.kalias@santhera.com
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #
Attachment
